Immunic Inc (NASDAQ: IMUX) announced unblinded safety, tolerability, and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD) of its phase 1 trial of IMU-856 in healthy human subjects.
In the SAD part of phase 1 clinical trial, healthy human subjects were randomized to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg.
Single ascending doses of IMU-856 were found to be safe and well-tolerated, and no maximum tolerated dose was reached.
No serious adverse events occurred.
Multiple ascending doses of IMU-856 were found to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment-emergent adverse events were primarily mild in severity.
The ongoing Part C of the phase 1 program is designed to assess the safety and tolerability of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge.
Approximately 42 patients are planned to be enrolled in two consecutive cohorts with 80 mg or 160 mg of IMU-856 given once daily over 28 days.
Price Action: IMUX shares are down 8.05% at $3.54 on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.